ConductScience.org, home

Paper · 39147708

References52

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134147721Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy.Biomaterials2021https://conductscience.org/library/papers/34147721PubMed
229434759miR-613 inhibits gastric cancer progression through repressing brain derived neurotrophic factor.Exp Ther Med2018https://conductscience.org/library/papers/29434759PubMed
322025255Neuropilin-1 expression in cancer and development.J Pathol2012https://conductscience.org/library/papers/22025255PubMed
433007840Radio-Resistance and DNA Repair in Pediatric Diffuse Midline Gliomas.Cancers (Basel)2020https://conductscience.org/library/papers/33007840PubMed
529790681Multiple primary lung cancer: A literature review.Adv Clin Exp Med2018https://conductscience.org/library/papers/29790681PubMed
629339084miR-613 inhibits cell migration and invasion by downregulating Daam1 in triple-negative breast cancer.Cell Signal2018https://conductscience.org/library/papers/29339084PubMed
735179953Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity.Sci Adv2022https://conductscience.org/library/papers/35179953PubMed
831289551High expression of miR-155 and miR-21 in the recurrence or metastasis of non-small cell lung cancer.Oncol Lett2019https://conductscience.org/library/papers/31289551PubMed
932150868Counteracting Radio-Resistance Using the Optimization of Radiotherapy.Int J Mol Sci2020https://conductscience.org/library/papers/32150868PubMed
1034506976Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.Acta Biomater2021https://conductscience.org/library/papers/34506976PubMed
1136568253Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer.Front Oncol2022https://conductscience.org/library/papers/36568253PubMed
1231833519Use of lung-specific exosomes for miRNA-126 delivery in non-small cell lung cancer.Nanoscale2020https://conductscience.org/library/papers/31833519PubMed
1334560422M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages.Biomaterials2021https://conductscience.org/library/papers/34560422PubMed
1436922504Engineered exosomes from different sources for cancer-targeted therapy.Signal Transduct Target Ther2023https://conductscience.org/library/papers/36922504PubMed
156307529Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor.Cell1983https://conductscience.org/library/papers/6307529PubMed
1631746532Responsive Exosome Nano-bioconjugates for Synergistic Cancer Therapy.Angew Chem Int Ed Engl2020https://conductscience.org/library/papers/31746532PubMed
1731122265The roles of glucose metabolic reprogramming in chemo- and radio-resistance.J Exp Clin Cancer Res2019https://conductscience.org/library/papers/31122265PubMed
1830030592Overview upon miR-21 in lung cancer: focus on NSCLC.Cell Mol Life Sci2018https://conductscience.org/library/papers/30030592PubMed
1911373684Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.Nature2001https://conductscience.org/library/papers/11373684PubMed
2031430455Cancer stem cell (CSC) resistance drivers.Life Sci2019https://conductscience.org/library/papers/31430455PubMed

papers-2026-11-12-0.1.0

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/papers/v1/39147708/references